NEW YORK – Quest Diagnostics said Thursday that it has collaborated with Australian diagnostics company Envision Sciences on a prostate cancer biomarker test.
The test, which Quest has launched through its AmeriPath pathology business, is intended to help doctors identify and differentiate potentially aggressive cases of prostate cancer.
Quest developed and validated the test under an intellectual property license agreement with Envision that provides for use of Envision's biomarker and immunohistochemistry technology. The test measures the levels of three protein markers: APPL1, sortilin, and syndecan-1. In a 2022 study published in Pathology, researchers found that 22 percent of prostate cancer specimens examined using a panel consisting of these three markers were upgraded and 20 percent were downgraded compared to conventional pathological assessment.
"Our goal for this innovative prostate biomarker test is to improve the accuracy of grading prostate cancer biopsies. We expect this service to help fill a clinical gap affecting millions of men for staging, diagnosis, and treatment for prostate cancer," Kristie Dolan, VP and general manager of Quest Diagnostics Oncology Franchise, said in a statement. "With Quest's national scale and industry-leading prostate cancer portfolio, we will be able to reach a larger number of patients and provide them with diagnostic insights to inform their treatment decisions."
"Our patented technology provides a novel approach to visualizing prostate cancer tissue and improving accuracy in grading the cancer by pathologists," Envision CEO Peter Pursey added. "We expect the test to enhance current prostate cancer histology practice and improve the information available to clinicians, enabling them to better align cancer grades with treatment options."